Autolus Therapeutics

$6.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-1.60%) As of 8:30 PM UTC today

Why Robinhood?

You can buy or sell AUTL and other stocks, options, and ETFs commission-free!

About AUTL

Autolus Therapeutics plc American Depositary Share, also called Autolus Therapeutics, is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. The listed name for AUTL is Autolus Therapeutics plc American Depositary Share.

CEO
Christian Martin Itin
Employees
292
Headquarters
London, Greater London
Founded
2018
Market Cap
480.86M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.62M
High Today
$7.01
Low Today
$6.60
Open Price
$6.98
Volume
530.92K
52 Week High
$17.19
52 Week Low
$3.00

AUTL Earnings

-$0.93
-$0.62
-$0.31
-$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.77 per share
Actual
Available Mar 4, Pre-Market
Preview Earnings Call

You May Also Like

IVOO
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure